<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01075425</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-12517</org_study_id>
    <secondary_id>NCI-2010-00127</secondary_id>
    <secondary_id>RC2CA148431</secondary_id>
    <nct_id>NCT01075425</nct_id>
  </id_info>
  <brief_title>Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome</brief_title>
  <official_title>Phase I Study of Belinostat (PXD-101) and Velcade (Bortezomib) in Relapsed or Refractory Acute Leukemia/ Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Belinostat and bortezomib may stop the growth of cancer cells by blocking some of&#xD;
      the enzymes needed for cell growth. Giving belinostat together with bortezomib may kill more&#xD;
      cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of&#xD;
      giving belinostat together with bortezomib in treating patients with relapsed or refractory&#xD;
      acute leukemia or myelodysplastic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES: I. To determine the recommended phase II doses for the combination of&#xD;
      bortezomib and belinostat in patients with relapsed or refractory acute leukemia (AL),&#xD;
      myelodysplasia (MDS), and chronic myelogenous leukemia in blast crisis. SECONDARY OBJECTIVES:&#xD;
      I. Determine safety and tolerance and describe the toxicities of the combination. II. To&#xD;
      demonstrate adequate methods for the assessment of pharmacodynamic response of leukemia cells&#xD;
      from the bone marrow and/or peripheral blood in terms of effects on NF-kB (nuclear RelA by&#xD;
      immunofluorescence microscopy), NF-kB dependent proteins XIAP and Bcl-xL, and BIM, and&#xD;
      document pharmacodynamic responses observed in the course of this study. III. To document&#xD;
      activity of the combination observed in the course of this study. OUTLINE: Patients receive&#xD;
      belinostat IV over 30 minutes on days 1-5 and 8-12 and bortezomib IV on days 1, 4, 8, and 11.&#xD;
      Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or&#xD;
      unacceptable toxicity. After completion of study treatment, patients are followed&#xD;
      periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended phase II doses for the combination of bortezomib and belinostat</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic response</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity of belinostat and bortezomib</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Acute Lymphocytic Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive belinostat IV over 30 minutes on days 1-5 and 8-12 and bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>PS-341</other_name>
    <other_name>VELCADE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>belinostat</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>PXD101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>sample collection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>western blotting</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Blotting, Western</other_name>
    <other_name>Western Blot</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>sample analysis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion&#xD;
&#xD;
          -  Relapsed or refractory acute leukemia&#xD;
&#xD;
          -  acute myeloid leukemia (AML) other than APL&#xD;
&#xD;
          -  acute lymphocytic leukemia (ALL)&#xD;
&#xD;
          -  acute leukemia that has evolved from a prior myelodysplastic syndrome - no requirement&#xD;
             for prior therapy&#xD;
&#xD;
          -  myelodysplastic Syndrome (MDS) - International Prognostic Scoring System (IPSS)&#xD;
             intermediate-2 or greater&#xD;
&#xD;
          -  chronic myelogenous leukemia with myeloid or lymphoid blast crisis&#xD;
&#xD;
          -  WBC =&lt; 50 x 10^9/L; hydroxyurea or leukopheresis may be used prior starting treatment&#xD;
&#xD;
          -  Prior allogeneic stem cell transplant is allowed provided that &gt;/= 12 months have&#xD;
             elapsed since allogeneic transplant; no graft versus host disease is present; not&#xD;
             currently on immunosuppressive therapy&#xD;
&#xD;
          -  AST, ALT =&lt; 2.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Female subject who is post-menopausal or surgically sterilized or willing to use an&#xD;
             acceptable method of birth control (i.e., oral or injectable hormonal methods; barrier&#xD;
             methods such as intra-uterine device, diaphragm with spermicide, condom with&#xD;
             spermicide, or abstinence) for the duration of the study&#xD;
&#xD;
          -  Male subject agrees to use an acceptable method for contraception for the duration of&#xD;
             the study&#xD;
&#xD;
          -  Serum total bilirubin =&lt; 1.5 x upper limit of normal&#xD;
&#xD;
          -  Serum potassium &gt;= 3.5 mEq/L and serum magnesium &gt;= 1.7 mEq/dL (electrolytes may be&#xD;
             corrected with supplementation)&#xD;
&#xD;
          -  ECOG Performance Status (PS) =&lt;2&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 x upper limit of normal or calculated or actual creatinine clearance&#xD;
             &gt; 45 mL/min&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          -  Willing and medically suitable for remission induction with other agents in&#xD;
             anticipation of a potentially curative allogeneic bone marrow transplant&#xD;
&#xD;
          -  Known CNS malignant disease&#xD;
&#xD;
          -  Prior severe allergic reactions to bortezomib, mannitol, boron, belinostat or&#xD;
             compounds of the hydroxamate class or arginine&#xD;
&#xD;
          -  Grade 1 with pain or Grade &gt;= 2 peripheral neuropathy or paresthesias within 14 days&#xD;
             before enrollment&#xD;
&#xD;
          -  History of sustained ventricular tachycardia, ventricular fibrillation, Torsade de&#xD;
             Pointes, or resuscitated cardiac arrest&#xD;
&#xD;
             â€¢ History of resuscitated cardiac arrest. Note: persons without pre-existing&#xD;
             cardiovascular comorbidities who have experienced resuscitated cardiac arrest in the&#xD;
             setting of sepsis ARE eligible provided they have no residual cardiac abnormalities&#xD;
             and providing they do not require ongoing medication to manage cardiac issues as an&#xD;
             outcome of such an event.&#xD;
&#xD;
          -  Conduction abnormality or concomitant treatment with an anti-arrhythmic agent to&#xD;
             prevent or control arrhythmia&#xD;
&#xD;
          -  Known congenital long QT syndrome&#xD;
&#xD;
          -  Clinically significant infection including infection with HIV, or active hepatitis B&#xD;
             or C&#xD;
&#xD;
          -  Significant cardiovascular disease, hypertrophic cardiomegaly or restrictive&#xD;
             cardiomyopathy, myocardial infarction within the past 6 months, unstable angina&#xD;
&#xD;
          -  Baseline QTc interval &gt; 450 msec&#xD;
&#xD;
          -  Planned or ongoing treatment with any drug that may be risk of causing Torsades de&#xD;
             Pointes&#xD;
&#xD;
          -  Persistent blood pressure (BP) of &gt;=160/95&#xD;
&#xD;
          -  Serious medical or psychiatric illness likely to interfere with patient participation&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Diagnosis or treatment for another malignancy within 3 years of enrollment, with the&#xD;
             exception of complete resection of basal cell carcinoma or squamous cell carcinoma of&#xD;
             the skin, an in situ malignancy, or low risk prostate cancer after curative therapy&#xD;
&#xD;
          -  Planned ongoing treatment with other drugs thought to potentially adversely interact&#xD;
             with belinostat&#xD;
&#xD;
          -  Strong or moderate CYP3A4 inhibitors&#xD;
&#xD;
          -  Patient has received other investigational drugs within 14 days before enrollment&#xD;
&#xD;
          -  If steroids for cancer control have been used, patients must be off these agents for&#xD;
             &gt;/= 1 week before starting treatment. Exception: maintenance therapy for non-malignant&#xD;
             disease with prednisone or steroid equivalent dose &lt; 10 mg/day is permitted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Grant</last_name>
    <role>Study Chair</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Beata Holkova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massey Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.massey.vcu.edu/</url>
    <description>VCU Massey Cancer Center</description>
  </link>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>February 15, 2010</study_first_submitted>
  <study_first_submitted_qc>February 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2010</study_first_posted>
  <last_update_submitted>April 13, 2016</last_update_submitted>
  <last_update_submitted_qc>April 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leukemia</keyword>
  <keyword>acute leukemia</keyword>
  <keyword>chronic myelogenous leukemia</keyword>
  <keyword>myelodysplastic syndrome</keyword>
  <keyword>relapsed acute leukemia</keyword>
  <keyword>refractory acute leukemia</keyword>
  <keyword>belinostat</keyword>
  <keyword>bortezomib</keyword>
  <keyword>Velcade</keyword>
  <keyword>PXD-101</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Belinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

